Literature DB >> 22968996

The role of dendritic cells in the generation of CD4(+) CD25(HI) Foxp3(+) T cells induced by amino acid copolymers.

Norio Kawamoto1, Hidenori Ohnishi, Naomi Kondo, Jack L Strominger.   

Abstract

The effects of the amino acid copolymers used in the therapy of experimental autoimmune encephalomyelitis, poly(Y,E,A,K)(n) (Copaxone(®)) and poly(Y,F,A,K)(n), on murine myeloid cells have been investigated. After administration of these copolymers to mice, increases in several splenic myeloid cell populations were observed, including CD11b(+) CD11c(+) dendritic cells. The latter were the major splenic cell type that secreted CCL22 (macrophage-derived chemokine) on stimulation with amino acid copolymers. CCL22 secretion was also stimulated from bone marrow-derived dendritic cells (BMDC) generated with GM-CSF in much larger amounts than from bone marrow-derived macrophages generated with M-CSF. Moreover, CCL22 secretion could also be obtained using BMDC generated from two different types of MHC II(-/-) mice, indicating that an innate immune receptor is involved. Finally, incubation of these BMDC or splenic dendritic cells with naive CD4(+) CD25(-) T cells resulted in formation of CD4(+) CD25(HI) Foxp3 T cells (~25% of which were Foxp3(+)). The number of these regulatory cells was doubled by pretreatment of BMDC with amino acid copolymers.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22968996      PMCID: PMC3619970          DOI: 10.1093/intimm/dxs087

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  57 in total

1.  Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide.

Authors:  D Teitelbaum; A Meshorer; T Hirshfeld; R Arnon; M Sela
Journal:  Eur J Immunol       Date:  1971-08       Impact factor: 5.532

2.  Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4.

Authors:  T Imai; D Chantry; C J Raport; C L Wood; M Nishimura; R Godiska; O Yoshie; P W Gray
Journal:  J Biol Chem       Date:  1998-01-16       Impact factor: 5.157

3.  Safety, pharmacokinetic, and pharmacodynamic evaluations of PI-2301, a potent immunomodulator, in a first-in-human, single-ascending-dose study in healthy volunteers.

Authors:  Joseph Kovalchin; Jeffrey Krieger; Kathy Collins; Michelle Genova; Michael Augustyniak; Allyson Masci; Tony Avril; Gwenola Gandon; Alain Patat; Nicolas Fauchoux; Claire Toutin; Eric Lacoste; Uday Patel; Edward Mascioli; Eric Zanelli
Journal:  J Clin Pharmacol       Date:  2010-10-12       Impact factor: 3.126

4.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

Authors:  K P Johnson; B R Brooks; J A Cohen; C C Ford; J Goldstein; R P Lisak; L W Myers; H S Panitch; J W Rose; R B Schiffer
Journal:  Neurology       Date:  1995-07       Impact factor: 9.910

5.  Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms.

Authors:  Joel N H Stern; Zsolt Illés; Jayagopala Reddy; Derin B Keskin; Eric Sheu; Masha Fridkis-Hareli; Hiroyuki Nishimura; Celia F Brosnan; Laura Santambrogio; Vijay K Kuchroo; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-03       Impact factor: 11.205

6.  Transfected human B lymphoblastoid cells express the mouse Ad beta-chain in association with DR alpha.

Authors:  M A Norcross; R Raghupathy; J Strominger; R N Germain
Journal:  J Immunol       Date:  1986-09-01       Impact factor: 5.422

7.  Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis.

Authors:  Ho Jin Kim; Igal Ifergan; Jack P Antel; Rosanne Seguin; Martin Duddy; Yves Lapierre; Farzaneh Jalili; Amit Bar-Or
Journal:  J Immunol       Date:  2004-06-01       Impact factor: 5.422

8.  Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.

Authors:  M Fridkis-Hareli; D Teitelbaum; E Gurevich; I Pecht; C Brautbar; O J Kwon; T Brenner; R Arnon; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

9.  Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses.

Authors:  D Teitelbaum; M Fridkis-Hareli; R Arnon; M Sela
Journal:  J Neuroimmunol       Date:  1996-02       Impact factor: 3.478

10.  Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells.

Authors:  R Godiska; D Chantry; C J Raport; S Sozzani; P Allavena; D Leviten; A Mantovani; P W Gray
Journal:  J Exp Med       Date:  1997-05-05       Impact factor: 14.307

View more
  4 in total

1.  Amino acid copolymers that alleviate experimental autoimmune encephalomyelitis in vivo interact with heparan sulfates and glycoprotein 96 in APCs.

Authors:  Paul-Albert Koenig; Eric Spooner; Norio Kawamoto; Jack L Strominger; Hidde L Ploegh
Journal:  J Immunol       Date:  2013-06-05       Impact factor: 5.422

2.  Genetically modified hematopoietic stem/progenitor cells that produce IL-10-secreting regulatory T cells.

Authors:  Sze-Ling Ng; Ester Leno-Duran; Dibyendu Samanta; Steven C Almo; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-25       Impact factor: 11.205

3.  CCL22 to Activate Treg Migration and Suppress Depigmentation in Vitiligo.

Authors:  Jonathan M Eby; Hee-Kap Kang; Sean T Tully; Wendy E Bindeman; Daniel S Peiffer; Shilpak Chatterjee; Shikhar Mehrotra; I Caroline Le Poole
Journal:  J Invest Dermatol       Date:  2015-01-09       Impact factor: 8.551

Review 4.  Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.

Authors:  Masha Fridkis-Hareli
Journal:  Clin Dev Immunol       Date:  2013-11-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.